19-Aug-2019: The global cell therapy
market size is expected to reach USD 7.92 billion by
2025, according to a new report by Grand View Research, Inc., rising at a CAGR
of 5.34% during the forecast period. Growing worldwide interest in discovering
and development of advanced therapy medicinal products that are based on genes,
tissues, or cells is likely to spur the growth of the market.
Companies and
research communities are witnessed to invest heavily in isolation and culturing
of a wide range of cell types, such as chondrocytes, keratinocytes, stem,
cartilage, dermal papilla, and epithelial cells for development of cell
therapies. Regulatory bodies are playing a crucial role in the growth of this
market by enforcing new laws pertaining to product development and approval.
Moreover, U.S. FDA
is engaged in keeping a check on practice of unauthorized therapies, which is
also one of the major concerns in the market. Direct cell reprogramming is
gaining attention as a novel therapeutic strategy owing to its efficacy and safety
advantages. Fortuna Fix, a privately-held company, aimed at becoming the first
company to bring in the clinical use of patient’s own neural stem cells,
produced by direct reprogramming for replacement of lost neuronal tissue in
neurotrauma and neurodegeneration. Such ongoing activities in this space are
anticipated to bolster the revenue generation in the future. Presence of
scientific concerns pertaining to the usage of these therapies necessitates
further studies for validation of clinical findings.
In
depth research report on Cell Therapy Market
Further key findings from the report suggest:
·
Currently, there are less number of approved products for
clinical use and withdrawal of several commercialized products. This has
resulted in lesser share of the clinical usage segment in the market
·
The research use segment is projected to exhibit a CAGR of
5.6% during the forecast period. Presence of a substantial number of R&D
projects is boosting investments in cell therapy for research use, thereby
bolstering the growth of the segment
·
Based on therapy type, allogenic therapies will remain the
most prominent segment throughout the forecast horizon. This is due to high
price and large number of companies involved in development of allogenic
therapies
·
On the other hand, autologous therapies are expected to post
a higher CAGR during the same period. Lack of donors and affordability are two
key drivers contributing to the growth of this segment
·
JCR Pharmaceuticals Co. Ltd.; Vericel Corporation; Osiris
Therapeutics, Inc.; and MEDIPOST are some key players operating in the market.
Companies are focusing in expanding their product portfolio and tapping into
the potential of the market.
Grand View Research
has segmented the global cell therapy market (stem & non-stem cells) on the
basis of use-type, therapy type, and region:
Cell Therapy (Stem & Non-Stem Cells) Use-type Outlook
(Revenue, USD Million, 2014 - 2025)
·
Clinical-use
o
By Therapeutic Area
·
Malignacies
·
Muscoskeletal disorders
·
Autoimmune disorders
·
Dermatology
·
Others
·
By Cell Type
§
Stem Cell Therapies
·
BM, Blood, & Umbilical Cord-derived Stem Cells
·
Adipose derived cells
·
Others
§
Non-stem Cell Therapies
·
Research-use
Cell Therapy (Stem & Non-Stem Cells) Therapy Type Outlook
(Revenue, USD Million, 2014 - 2025)
·
Allogenic Therapies
·
Autologous Therapies
Browse
more research reports of this category:
About
Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, the company offers market
intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and
energy.
No comments:
Post a Comment